Products for Research Use Only

HAChE-IN-3

CAT: 0804-HY-155085Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-155085Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HAChE-IN-3 (compounds 5c) is a potent and blood-brain barrier permeable AChE, BuChE, MAO-B-IN-1 and BACE-1 inhibitor, with IC50 values of 0.44, 0.08, 5.15 and 0.38 μM, respectively. hAChE-IN-3 has antioxidant activity and metal chelating ability. In addition, hAChE-IN-3 can bind to peripheral anion sites, and affect β amyloid and reduce Alzheimer's-associated neurodegeneration. hAChE-IN-3 has the potential for the research of Alzheimer's disease[1].
CAS Number
2983723-56-2
UNSPSC
12352005
Target
Amyloid-β; Cholinesterase (ChE) ; Monoamine Oxidase
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/hache-in-3.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(Cl)C=C1)COC2=CC3=C(C=C2)C(C4=CC=CC([N+]([O-])=O)=C4)C5=C(N)C6=C(N=C5O3)CCCC6
Molecular Formula
C30H24ClN3O5
Molecular Weight
541.98
References & Citations
[1]Salma Fares, et al. Modified Tacrine Derivatives as Multitarget-Directed Ligands for the Treatment of Alzheimer’sDisease: Synthesis, Biological Evaluation, and Molecular Modeling Study. ACS Omega 2023, 8, 29, 26012–26034.|[2]Salma Fares, et al. Modified Tacrine Derivatives as Multitarget-Directed Ligands for the Treatment of Alzheimer’sDisease: Synthesis, Biological Evaluation, and Molecular Modeling Study. ACS Omega 2023, 8, 29, 26012–26034.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
AChE; BChE; MAO-B